 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does HALOPERIDOL increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes HALOPERIDOL increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes HALOPERIDOL increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does HALOPERIDOL increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"HALOPERIDOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: HALOPERIDOL: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Haloperidol is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Cardiovascular Effects Cases of sudden death, [0m
[31mQT-prolongation, and Torsades de pointes have been reported in patients receiving haloperidol. Higher than recommended doses of any formulation of haloperidol appear to be associated with a higher [0m
[31mrisk of QT-prolongation and Torsades de pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other [0m
[31mQT-prolonging conditions [0m[1;31m([0m[31mincluding electrolyte imbalance [0m[31m, drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome[0m[1;31m)[0m[31m. HALOPERIDOL: warnings: Tardive [0m
[31mDyskinesia A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. Both the risk of developing tardive dyskinesia and the likelihood that it[0m
[31mwill become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can [0m
[31mdevelop, although much less commonly, after relatively brief treatment periods at low doses. HALOPERIDOL: warnings: There is no known treatment for established cases of tardive dyskinesia, although [0m
[31mthe syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who[0m
[31msuffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and, [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are not available or [0m
[31mappropriate. HALOPERIDOL: warnings: In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. [0m
[31mThe need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. [0m
[31mHowever, some patients may require treatment despite the presence of the syndrome. [0m[1;31m([0m[31mFor further information about the description of tardive dyskinesia and its clinical detection, please refer to [0m
[31mADVERSE REACTIONS .[0m[1;31m)[0m[31m Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m has been reported in association with [0m
[31mantipsychotic drugs.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: warnings: Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status [0m[1;31m([0m[31mincluding catatonic signs[0m[1;31m)[0m[31m and evidence of autonomic instability [0m[1;31m([0m[31mirregular [0m
[31mpulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. Additional signs may include elevated creatine phosphokinase, myoglobinuria [0m[1;31m([0m[31mrhabdomyolysis[0m[1;31m)[0m[31m and acute renal failure. The [0m
[31mdiagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness[0m
[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. Other important considerations in the differential diagnosis include central [0m
[31manticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. HALOPERIDOL: warnings: The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of [0m
[31mantipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical monitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for [0m
[31mwhich specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after[0m
[31mrecovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia and[0m
[31mheat stroke, not associated with the above symptom complex, have also been reported with haloperidol. Falls Haloperidol tablets, USP may cause somnolence, postural hypotension, motor and sensory [0m
[31minstability, which may lead to falls and, consequently, fractures or other injuries. HALOPERIDOL: warnings: For patients with diseases, conditions, or medications that could exacerbate these effects, [0m
[31mcomplete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Usage in Pregnancy Pregnancy Nonteratogenic Effects Neonates [0m
[31mexposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, [0m
[31mhypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other [0m
[31mcases neonates have required intensive care unit support and prolonged hospitalization. Haloperidol should be used during pregnancy only if the potential benefit justifies the potential risk to the [0m
[31mfetus. HALOPERIDOL: warnings: Rodents given [0m[1;31m2[0m[31m to [0m[1;31m20[0m[31m times the usual maximum human dose of haloperidol by oral or parenteral routes showed an increase in incidence of resorption, reduced fertility, [0m
[31mdelayed delivery and pup mortality. No teratogenic effect has been reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given [0m[1;31m15[0m[31m times the usual [0m
[31mmaximum human dose. Cleft palate in mice appears to be a nonspecific response to stress or nutritional imbalance as well as to a variety of drugs, and there is no evidence to relate this phenomenon to[0m
[31mpredictable human risk for most of these agents. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following [0m
[31mmaternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. [0m
[31mHALOPERIDOL: warnings: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only [0m
[31mif the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Combined Use of Haloperidol and Lithium An encephalopathic syndrome [0m[1;31m([0m[31mcharacterized [0m
[31mby weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS[0m[1;31m)[0m[31m followed by irreversible brain damage has occurred in a few [0m
[31mpatients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients [0m
[31mreceiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear. HALOPERIDOL: general_precautions: [0m
[31mGeneral A number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. It has been postulated that lethargy and decreased sensation of thirst [0m
[31mdue to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, especially in the elderly, the physician [0m
[31mshould institute remedial therapy promptly. Although not reported with haloperidol, decreased serum cholesterol and/or cutaneous and ocular changes have been reported in patients receiving [0m
[31mchemically-related drugs. Haloperidol may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The [0m
[31mambulatory patient should be warned accordingly. The use of alcohol with this drug should be avoided due to possible additive effects and hypotension.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: adverse_reactions: It is not known whether gradual withdrawal of antipsychotic drugs will reduce the rate of occurrence of withdrawal emergent neurological signs but until [0m
[31mfurther evidence becomes available, it seems reasonable to gradually withdraw use of haloperidol. Tardive Dyskinesia As with all antipsychotic agents, haloperidol has been associated with persistent [0m
[31mdyskinesias. Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy [0m
[31mhas been discontinued. The risk appears to be greater in elderly patients on high dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome [0m
[31mis characterized by rhythmical involuntary movements of tongue, face, mouth or jaw [0m[1;31m([0m[31me.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements[0m[1;31m)[0m[31m. Sometimes these may be [0m
[31maccompanied by involuntary movements of extremities and the trunk. HALOPERIDOL: adverse_reactions: There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not [0m
[31malleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage[0m
[31mof the agent, or switch to a different antipsychotic agent, this syndrome may be masked. It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and[0m
[31mif the medication is stopped at that time, the full syndrome may not develop. Tardive Dystonia Tardive dystonia, not associated with the above syndrome, has also been reported. Tardive dystonia is [0m
[31mcharacterized by delayed onset of choreic or dystonic movements, is often persistent, and has the potential of becoming irreversible. HALOPERIDOL: adverse_reactions: Other CNS Effects Insomnia, [0m
[31mrestlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations and [0m
[31mcatatonic-like behavioral states which may be responsive to drug withdrawal and/or treatment with anticholinergic drugs. Body as a Whole: Neuroleptic malignant syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m, hyperpyrexia and heat [0m
[31mstroke have been reported with haloperidol. [0m[1;31m([0m[31mSee WARNINGS for further information concerning NMS.[0m[1;31m)[0m[31m Hematologic Effects: Reports have appeared citing the occurrence of mild and usually transient [0m
[31mleukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of [0m
[31mhaloperidol, and then only in association with other medication. HALOPERIDOL: adverse_reactions: Liver Effects: Impaired liver function and/or jaundice have been reported. Dermatologic Reactions: [0m
[31mMaculopapular and acneiform skin reactions and isolated cases of photosensitivity and loss of hair. Endocrine Disorders: Lactation, breast engorgement, mastalgia, menstrual irregularities, [0m
[31mgynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and hyponatremia. Gastrointestinal Effects: Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting. [0m
[31mAutonomic Reactions: Dry mouth, blurred vision, urinary retention, diaphoresis and priapism. Respiratory Effects: Laryngospasm, bronchospasm and increased depth of respiration. Special Senses: [0m
[31mCataracts, retinopathy and visual disturbances. HALOPERIDOL: adverse_reactions: Post-marketing Events Hyperammonemia has been reported in a [0m[1;31m5[0m[31m-[0m[1;31m1[0m[31m‚ÅÑ[0m[1;31m2[0m[31m year old child with citrullinemia, an inherited [0m
[31mdisorder of ammonia excretion, following treatment with haloperidol.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. HALOPERIDOL: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Haloperidol is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m


[31mCONTENT: HALOPERIDOL: precautions: PRECAUTIONS Leukopenia, Neutropenia and Agranulocytosis In clinical trial and post-marketing experience, events of leukopenia/neutropenia have been reported [0m
[31mtemporally related to antipsychotic agents, including haloperidol. Agranulocytosis [0m[1;31m([0m[31mincluding fatal cases[0m[1;31m)[0m[31m has also been reported. Possible risk factors for leukopenia/neutropenia include preexisting [0m
[31mlow white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced leukopenia/neutropenia. Patients with a preexisting low WBC or a history of drug induced leukopenia/neutropenia should have their complete [0m
[31mblood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the first few months of therapy and should discontinue haloperidol at the first sign of a decline in WBC in the absence of other causative factors. [0m
[31mHALOPERIDOL: precautions: Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with [0m
[31msevere neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1[0m[31m,[0m[1;31m000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue haloperidol and have their WBC followed until recovery. Haloperidol should be administered cautiously to patients: -with[0m
[31msevere cardiovascular disorders, because of the possibility of transient hypotension and/or precipitation of anginal pain. Should hypotension occur and a vasopressor be required, epinephrine should [0m
[31mnot be used since haloperidol may block its vasopressor activity and paradoxical further lowering of the blood pressure may occur. Instead, metaraminol, phenylephrine or norepinephrine should be used.[0m
[31m-receiving anticonvulsant medications, with a history of seizures, or with EEG abnormalities, because haloperidol may lower the convulsive threshold. HALOPERIDOL: precautions: If indicated, adequate [0m
[31manticonvulsant therapy should be concomitantly maintained. -with known allergies, or with a history of allergic reactions to drugs. -receiving anticoagulants, since an isolated instance of [0m
[31minterference occurred with the effects of one anticoagulant [0m[1;31m([0m[31mphenindione[0m[1;31m)[0m[31m. If concomitant antiparkinson medication is required, it may have to be continued after haloperidol is discontinued because of[0m
[31mthe difference in excretion rates. If both are discontinued simultaneously, extrapyramidal symptoms may occur. The physician should keep in mind the possible increase in intraocular pressure when [0m
[31manticholinergic drugs, including antiparkinson agents, are administered concomitantly with haloperidol. As with other antipsychotic agents, it should be noted that haloperidol may be capable of [0m
[31mpotentiating CNS depressants such as anesthetics, opiates, and alcohol. HALOPERIDOL: precautions: In a study of [0m[1;31m12[0m[31m schizophrenic patients coadministered haloperidol and rifampin, plasma haloperidol [0m
[31mlevels were decreased by a mean of [0m[1;31m70[0m[31m% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline. In five other schizophrenic patients treated with haloperidol and rifampin, [0m
[31mdiscontinuation of rifampin produced a mean [0m[1;31m3.3[0m[31m-fold increase in haloperidol concentrations. Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in [0m
[31mhaloperidol-treated patients. When haloperidol is used to control mania in cyclic disorders, there may be a rapid mood swing to depression. Severe neurotoxicity [0m[1;31m([0m[31mrigidity, inability to walk or talk[0m[1;31m)[0m[31m [0m
[31mmay occur in patients with thyrotoxicosis who are also receiving antipsychotic medication, including haloperidol. HALOPERIDOL: precautions: No mutagenic potential of haloperidol was found in the Ames [0m
[31mSalmonella microsomal activation assay. Negative or inconsistent positive findings have been obtained in in vitro and in vivo studies of effects of haloperidol on chromosome structure and number. The [0m
[31mavailable cytogenetic evidence is considered too inconsistent to be conclusive at this time. Carcinogenicity studies using oral haloperidol were conducted in Wistar rats [0m[1;31m([0m[31mdosed at up to [0m[1;31m5[0m[31m mg/kg daily [0m
[31mfor [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m and in Albino Swiss mice [0m[1;31m([0m[31mdosed at up to [0m[1;31m5[0m[31m mg/kg daily for [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m. In the rat study, survival was less than optimal in all dose groups, reducing the number of rats at risk for [0m
[31mdeveloping tumors. However, although a relatively greater number of rats survived to the end of the study in high dose male and female groups, these animals did not have a greater incidence of tumors [0m
[31mthan control animals. HALOPERIDOL: precautions: Therefore, although not optimal, this study does suggest the absence of a haloperidol related increase in the incidence of neoplasia in rats at doses up[0m
[31mto [0m[1;31m20[0m[31m times the usual daily human dose for chronic or resistant patients. In female mice at [0m[1;31m5[0m[31m and [0m[1;31m20[0m[31m times the highest initial daily dose for chronic or resistant patients, there was a statistically [0m
[31msignificant increase in mammary gland neoplasia and total tumor incidence; at [0m[1;31m20[0m[31m times the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no[0m
[31mstatistically significant differences in incidences of total tumors or specific tumor types were noted. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic [0m
[31madministration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these[0m
[31mdrugs is contemplated in a patient with a previously detected breast cancer. HALOPERIDOL: precautions: Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been [0m
[31mreported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of [0m
[31mantipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; [0m
[31mthe available evidence is considered too limited to be conclusive at this time. There are no well controlled studies with haloperidol in pregnant women. There are reports, however, of cases of limb [0m
[31mmalformations observed following maternal use of haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not [0m
[31mestablished in these cases. HALOPERIDOL: precautions: Since such experience does not exclude the possibility of fetal damage due to haloperidol, this drug should be used during pregnancy or in women [0m
[31mlikely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment. Pediatric Use Safety and effectiveness in pediatric [0m
[31mpatients have not been established. Geriatric Use Clinical studies of haloperidol did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from [0m
[31myounger subjects. Other reported clinical experience has not consistently identified differences in responses between the elderly and younger patients. However, the prevalence of tardive dyskinesia [0m
[31mappears to be highest among the elderly, especially elderly women [0m[1;31m([0m[31msee WARNINGS: Tardive Dyskinesia [0m[1;31m)[0m[31m. Also, the pharmacokinetics of haloperidol in geriatric patients generally warrants the use of [0m
[31mlower doses [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:HALOPERIDOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: HALOPERIDOL has been reported to have a risk of causing agranulocytosis, which is a severe and potentially fatal reduction in white blood cell count. However, there is no specific mention of [0m
[32maplastic anemia as a risk associated with HALOPERIDOL in the provided extracts.[0m

[32mSOURCE: HALOPERIDOL label[0m
[32mEXTRACT_START_END: Agranulocytosis has rarely been reported[0m[32m...[0m[32mwith the use of haloperidol.[0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: HALOPERIDOL has been reported to have a risk of causing [0m
[34magranulocytosis, which is a severe and potentially fatal reduction in white blood cell count. However, there is no specific mention of aplastic anemia as a risk associated with HALOPERIDOL in the [0m
[34mprovided extracts.[0m

[34mSOURCE: HALOPERIDOL label[0m
[34mEXTRACT_START_END: Agranulocytosis has rarely been reported[0m[34m...[0m[34mwith the use of haloperidol.[0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does HALOPERIDOL increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether HALOPERIDOL increases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that HALOPERIDOL has been reported to have a risk of causing agranulocytosis, which is a severe reduction in white blood cell count, but there is no specific mention of [0m
[32maplastic anemia in the HALOPERIDOL label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for HALOPERIDOL does not specifically mention an increased risk of aplastic anemia. However, it does note a risk of agranulocytosis, which is a different but severe [0m
[32mcondition involving a reduction in white blood cell count. Therefore, based on the FDA label, we cannot conclusively say that HALOPERIDOL increases or decreases the risk of aplastic anemia."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does HALOPERIDOL increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether HALOPERIDOL increases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that HALOPERIDOL has been reported to have a risk of causing agranulocytosis, which is a severe reduction in white blood cell count, but there is no specific mention of [0m
[34maplastic anemia in the HALOPERIDOL label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for HALOPERIDOL does not specifically mention an increased risk of aplastic anemia. However, it does note a risk of agranulocytosis, which is a different but severe [0m
[34mcondition involving a reduction in white blood cell count. Therefore, based on the FDA label, we cannot conclusively say that HALOPERIDOL increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does HALOPERIDOL increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether HALOPERIDOL increases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that HALOPERIDOL has been reported to have a risk of causing agranulocytosis, which is a severe reduction in white blood cell count, but there is no specific mention of [0m
[31maplastic anemia in the HALOPERIDOL label.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for HALOPERIDOL does not specifically mention an increased risk of aplastic anemia. However, it does note a risk of agranulocytosis, which is a different but severe[0m
[31mcondition involving a reduction in white blood cell count. Therefore, based on the FDA label, we cannot conclusively say that HALOPERIDOL increases or decreases the risk of aplastic anemia.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the guidelines. The user has correctly stated that the FDA label does not specifically mention an increased risk of aplastic anemia for [0m
[32mHALOPERIDOL but does mention agranulocytosis. The user has made a clear distinction between the two conditions and has appropriately concluded that the information available does not allow for a [0m
[32mconclusive statement about the effect of HALOPERIDOL on the risk of aplastic anemia. No flaws are identified in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the guidelines. The user has correctly stated that the FDA label does not specifically mention an increased risk of aplastic anemia for [0m
[34mHALOPERIDOL but does mention agranulocytosis. The user has made a clear distinction between the two conditions and has appropriately concluded that the information available does not allow for a [0m
[34mconclusive statement about the effect of HALOPERIDOL on the risk of aplastic anemia. No flaws are identified in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the guidelines. The user has correctly stated that the FDA label does not specifically mention an increased risk of aplastic anemia for [0m
[31mHALOPERIDOL but does mention agranulocytosis. The user has made a clear distinction between the two conditions and has appropriately concluded that the information available does not allow for a [0m
[31mconclusive statement about the effect of HALOPERIDOL on the risk of aplastic anemia. No flaws are identified in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-HALOPERIDOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for HALOPERIDOL does not specifically mention an increased risk of aplastic anemia. However, it does note a risk of agranulocytosis, which is a different but severe condition involving a[0m
[32mreduction in white blood cell count. Therefore, based on the FDA label, we cannot conclusively say that HALOPERIDOL increases or decreases the risk of aplastic anemia.[0m
